104 related articles for article (PubMed ID: 38958425)
1. How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?
Salisbury-Afshar E; Livingston CJ; Bluthenthal RN
AMA J Ethics; 2024 Jul; 26(7):E562-571. PubMed ID: 38958425
[TBL] [Abstract][Full Text] [Related]
2. Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program.
Ashford RD; Curtis B; Brown AM
Harm Reduct J; 2018 Oct; 15(1):52. PubMed ID: 30348170
[TBL] [Abstract][Full Text] [Related]
3. The Opioid Epidemic in NC: Progress, Challenges, and Opportunities.
Kansagra SM; Cohen MK
N C Med J; 2018; 79(3):157-162. PubMed ID: 29735617
[TBL] [Abstract][Full Text] [Related]
4. Harm Reduction Strategies for the Opiod Crisis.
Castillo T
N C Med J; 2018; 79(3):192-194. PubMed ID: 29735629
[TBL] [Abstract][Full Text] [Related]
5. Harm Reduction: Front Line Public Health.
Stancliff S; Phillips BW; Maghsoudi N; Joseph H
J Addict Dis; 2015; 34(2-3):206-19. PubMed ID: 26080038
[TBL] [Abstract][Full Text] [Related]
6. Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond.
Barnett BS; Wakeman SE; Davis CS; Favaro J; Rich JD
Am J Public Health; 2021 Jun; 111(6):1013-1017. PubMed ID: 33950718
[No Abstract] [Full Text] [Related]
7. High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants.
Barocas JA; Baker L; Hull SJ; Stokes S; Westergaard RP
Drug Alcohol Depend; 2015 Sep; 154():283-6. PubMed ID: 26143300
[TBL] [Abstract][Full Text] [Related]
8. Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies.
Hawk KF; Vaca FE; D'Onofrio G
Yale J Biol Med; 2015 Sep; 88(3):235-45. PubMed ID: 26339206
[TBL] [Abstract][Full Text] [Related]
9. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
Pizzicato LN; Johnson CC; Viner KM
Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
[No Abstract] [Full Text] [Related]
10. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
11. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
[TBL] [Abstract][Full Text] [Related]
12. NEXT Harm Reduction: An Online, Mail-Based Naloxone Distribution and Harm-Reduction Program.
Yang C; Favaro J; Meacham MC
Am J Public Health; 2021 Apr; 111(4):667-671. PubMed ID: 33600254
[TBL] [Abstract][Full Text] [Related]
13. Collaborative approach to harm reduction by managed care pharmacy team for populations with substance use disorder.
Osibanjo O; Reinhardt R; Clemans S; Andoniadis S; Carson P; Benkstein K
J Am Pharm Assoc (2003); 2023; 63(1):396-402. PubMed ID: 36564331
[TBL] [Abstract][Full Text] [Related]
14. Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice.
Gugala E; Briggs O; Moczygemba LR; Brown CM; Hill LG
Subst Abus; 2022; 43(1):972-987. PubMed ID: 35426772
[No Abstract] [Full Text] [Related]
15. Harm Reduction in Health Care Settings.
Chan CA; Canver B; McNeil R; Sue KL
Med Clin North Am; 2022 Jan; 106(1):201-217. PubMed ID: 34823731
[TBL] [Abstract][Full Text] [Related]
16. Use of harm reduction strategies by individuals with a history of incarceration: A short report using baseline data collected from the STAMINA clinical trial.
Victor G; Ray B; Watson DP
J Subst Use Addict Treat; 2024 Jul; 162():209376. PubMed ID: 38641053
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids.
Winhusen T; Wilder C; Lyons MS; Theobald J; Kropp F; Lewis D
Drug Alcohol Depend; 2020 Nov; 216():108265. PubMed ID: 32919098
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an Unsanctioned Safe Consumption Site in the United States.
Kral AH; Lambdin BH; Wenger LD; Davidson PJ
N Engl J Med; 2020 Aug; 383(6):589-590. PubMed ID: 32640126
[No Abstract] [Full Text] [Related]
19. Attitudes toward syringe exchange programs in a rural Appalachian community.
Zeller TA; Beachler T; Diaz L; Thomas RP; Heo M; Lanzillotta-Rangeley J; Litwin AH
J Addict Dis; 2022; 40(2):227-234. PubMed ID: 34550054
[TBL] [Abstract][Full Text] [Related]
20. How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?
Dong KA; Duthie KM
AMA J Ethics; 2024 Jul; 26(7):E512-519. PubMed ID: 38958419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
